NeuroPace (NPCE) Cash from Investing Activities (2020 - 2026)
NeuroPace's (NPCE) quarterly Cash from Investing Activities came in at -$117000.0 in Q1 2026, down 216.22% year-on-year from $100674.4 in Q1 2025, and down 20.62% quarter-over-quarter from -$97000.0 in Q4 2025.
NeuroPace (NPCE) Cash from Investing Activities (2020 - 2026) Analysis & Trends
NeuroPace's Cash from Investing Activities history runs 7 years deep, the most recent figure standing at -$117000.0 for Q1 2026.
- On a quarterly basis, Cash from Investing Activities fell 216.22% year-over-year to -$117000.0 in Q1 2026; TTM through Mar 2026 was -$412000.0, a 106.28% decrease from a year earlier, with the FY2025 full-year figure at -$332000.0, down 103.69% from the prior year.
- Cash from Investing Activities fell to -$117000.0 in Q1 2026 per NPCE's latest filing, from -$97000.0 in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $10.1 million in Q1 2023 and bottomed at -$306000.0 in Q1 2022.
- The 5-year median for Cash from Investing Activities is $2.4 million (2024), against an average of $3.3 million.
- Across the five-year window, Cash from Investing Activities jumped 5877.92% in 2022 and plunged 216.22% in 2026, its largest moves.
- Year by year, Cash from Investing Activities stood at $8.9 million in 2022, then tumbled by 61.02% to $3.5 million in 2023, then tumbled by 43.45% to $2.0 million in 2024, then plunged by 104.95% to -$97000.0 in 2025, then retreated by 20.62% to -$117000.0 in 2026.
- Per Business Quant, the three latest NPCE Cash from Investing Activities figures stand at -$117000.0 (Q1 2026), -$97000.0 (Q4 2025), and -$30000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.13 Bn | 175.83 Bn | 6.27 Bn | -20.32 Bn |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | -185.00 Mn |
| 3 | Medtronic | 108.98 Bn | 99.76 Bn | 6.41 Bn | -917.00 Mn |
| 4 | Boston Scientific | 68.45 Bn | 67.00 Bn | 3.61 Bn | -591.00 Mn |
| 5 | Edwards Lifesciences | 48.01 Bn | 44.34 Bn | 1.29 Bn | -92.80 Mn |
| 6 | GE HealthCare Technologies | 28.29 Bn | 26.01 Bn | 1.98 Bn | -2.50 Bn |
| 7 | Dexcom | 28.25 Bn | 27.13 Bn | 750.30 Mn | -298.50 Mn |
| 8 | Smith & Nephew | 26.91 Bn | 26.33 Bn | - | - |
| 9 | Koninklijke Philips | 25.45 Bn | 22.32 Bn | 2.07 Bn | -475.32 Mn |
| 10 | NeuroPace | 516.20 Mn | 462.22 Mn | 18.05 Mn | -117,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -117,000.00 |
| Mar 31, 2026 | -117,000.00 |
| Dec 31, 2025 | -97,000.00 |
| Dec 31, 2025 | -97,000.00 |
| Sep 30, 2025 | -30,000.00 |
| Sep 30, 2025 | -30,000.00 |
| Jun 30, 2025 | -168,000.00 |
| Jun 30, 2025 | -168,000.00 |
| Mar 31, 2025 | -37,000.00 |
| Mar 31, 2025 | -37,000.00 |
| Dec 31, 2024 | 1.96 Mn |
| Dec 31, 2024 | 1.96 Mn |
| Sep 30, 2024 | 1.40 Mn |
| Sep 30, 2024 | 1.40 Mn |
| Jun 30, 2024 | 3.24 Mn |
| Jun 30, 2024 | 3.24 Mn |
| Mar 31, 2024 | 2.40 Mn |
| Mar 31, 2024 | 2.40 Mn |
| Dec 31, 2023 | 3.47 Mn |
| Dec 31, 2023 | 3.47 Mn |